ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -133.2 Million EUR | -132.06% |
| 2022 | -53.31 Million EUR | -8.73% |
| 2021 | -42.19 Million EUR | -31.63% |
| 2020 | -39.53 Million EUR | -19.08% |
| 2019 | -33.21 Million EUR | -74.36% |
| 2018 | -19.22 Million EUR | -35.43% |
| 2017 | -14.05 Million EUR | 22.64% |
| 2016 | -17.73 Million EUR | -0.28% |
| 2015 | -18.11 Million EUR | -108.3% |
| 2014 | -5 Million EUR | -17.95% |
| 2013 | -7.37 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -79.82 Million EUR | 0.0% |
| 2023 Q2 | -39.2 Million EUR | 0.0% |
| 2023 FY | - EUR | -132.06% |
| 2023 Q4 | -90.04 Million EUR | 0.0% |
| 2022 Q2 | -18.58 Million EUR | 0.0% |
| 2022 Q4 | -37.98 Million EUR | 0.0% |
| 2022 FY | - EUR | -8.73% |
| 2021 FY | - EUR | -31.63% |
| 2021 Q2 | -26.5 Million EUR | 0.0% |
| 2021 Q4 | -25.56 Million EUR | 0.0% |
| 2020 Q2 | -16.17 Million EUR | 0.0% |
| 2020 Q4 | -23.35 Million EUR | 0.0% |
| 2020 FY | - EUR | -19.08% |
| 2019 Q2 | -17.16 Million EUR | 0.0% |
| 2019 FY | - EUR | -74.36% |
| 2019 Q4 | -16.03 Million EUR | 0.0% |
| 2018 FY | - EUR | -35.43% |
| 2018 Q4 | -10.51 Million EUR | 0.0% |
| 2018 Q2 | -8.51 Million EUR | 0.0% |
| 2017 FY | - EUR | 22.64% |
| 2017 Q4 | -6.69 Million EUR | 0.0% |
| 2017 Q2 | -7.36 Million EUR | 0.0% |
| 2016 FY | - EUR | -0.28% |
| 2016 Q2 | -10.58 Million EUR | 0.0% |
| 2016 Q4 | -7.58 Million EUR | 0.0% |
| 2015 Q2 | -8.07 Million EUR | 0.0% |
| 2015 FY | - EUR | -108.3% |
| 2015 Q4 | -10.04 Million EUR | 0.0% |
| 2014 Q4 | -5 Million EUR | -237385.17% |
| 2014 FY | - EUR | -17.95% |
| 2014 Q1 | 103.50 EUR | 0.0% |
| 2014 Q2 | 211 Thousand EUR | 203764.73% |
| 2014 Q3 | -2107.50 EUR | -101.0% |
| 2013 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -3948.845% |
| Adocia SA | -22.73 Million EUR | -485.989% |
| Aelis Farma SA | -6.34 Million EUR | -1998.74% |
| Biophytis S.A. | -13.8 Million EUR | -864.988% |
| Advicenne S.A. | -6.24 Million EUR | -2033.36% |
| genOway Société anonyme | 6.35 Million EUR | 2197.5% |
| IntegraGen SA | -52.5 Thousand EUR | -253613.121% |
| Medesis Pharma S.A. | -3.84 Million EUR | -3364.526% |
| Neovacs S.A. | -8.44 Million EUR | -1476.499% |
| NFL Biosciences SA | -4.04 Million EUR | -3189.629% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 183757.797% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -4535.738% |
| Sensorion SA | -22.31 Million EUR | -496.971% |
| Theranexus Société Anonyme | -7.38 Million EUR | -1703.206% |
| TME Pharma N.V. | -5.07 Million EUR | -2526.321% |
| Valbiotis SA | -6.95 Million EUR | -1815.27% |
| TheraVet SA | -517.33 Thousand EUR | -25648.643% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -604.203% |
| argenx SE | -199.5 Million EUR | 33.232% |
| BioSenic S.A. | -6.79 Million EUR | -1860.079% |
| Celyad Oncology SA | -7.76 Million EUR | -1615.922% |
| DBV Technologies S.A. | -79.53 Million EUR | -67.491% |
| Galapagos NV | 51.03 Million EUR | 361.001% |
| Genfit S.A. | -28.05 Million EUR | -374.874% |
| GeNeuro SA | -14.31 Million EUR | -830.366% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -789.232% |
| Innate Pharma S.A. | -7.57 Million EUR | -1657.812% |
| Inventiva S.A. | -101.84 Million EUR | -30.79% |
| MaaT Pharma SA | -19.74 Million EUR | -574.807% |
| MedinCell S.A. | -20.04 Million EUR | -564.507% |
| Nanobiotix S.A. | -34.01 Million EUR | -291.566% |
| Onward Medical N.V. | -35.23 Million EUR | -278.064% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -2904.652% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | -472.539% |
| Oxurion NV | -16.72 Million EUR | -696.264% |
| Pharming Group N.V. | 4.98 Million EUR | 2774.321% |
| Poxel S.A. | -12.17 Million EUR | -993.743% |
| GenSight Biologics S.A. | -21.73 Million EUR | -513.01% |
| Transgene SA | -27.02 Million EUR | -392.921% |
| Financière de Tubize SA | 184.57 Thousand EUR | 72271.143% |
| UCB SA | 1.26 Billion EUR | 110.497% |
| Valneva SE | -64.51 Million EUR | -106.468% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | -369.816% |